Machine Learning Models for the Prediction of Chemotherapy-Induced Peripheral Neuropathy
Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse side effect of cancer chemotherapy that can be life debilitating and cause extreme pain. The multifactorial and poorly understood mechanisms of toxicity have impeded the identification of novel treatment strategies. Computational models of drug neurotoxicity could be implemented in early drug discovery to screen for high-risk compounds and select safer drug candidates for further development.
Quantitative-structure toxicity relationship (QSTR) models were developed to predict the incidence of PN. A manually curated library of 95 approved drugs were used to develop the model. Molecular descriptors sensitive to the incidence of PN were identified to provide insights into structural modifications to reduce neurotoxicity. The incidence of PN was predicted for 60 antineoplastic drug candidates currently under clinical investigation.
The number of aromatic nitrogens was identified as the most important molecular descriptor. The chemical transformation of aromatic nitrogens to carbons reduced the predicted PN incidence of bortezomib from 32.3% to 21.1%. Antineoplastic drug candidates were categorized into three groups (high, medium, low) based on their predicted PN incidence.
QSTR models were developed to link physicochemical descriptors of compounds with PN incidence, which can be utilized during drug candidate selection to reduce neurotoxicity.
KeywordsADMET predictor chemotherapy-induced peripheral neuropathy machine learning toxicity QSAR
Absorption, distribution, metabolism, excretion, and toxicity
Artificial neural network
Common terminology criteria for adverse events
Chemotherapy-induced peripheral neuropathy
European Organization for Research and Treatment of Cancer
European Medicines Agency
Food and Drug Administration
National Cancer Institute
Pharmacokinetic and pharmacodynamic
Quality of Life Questionnaire-CIPN20
Quantitative structure-activity relationship
Quantitative-structure toxicity relationship
Support vector machine
Acknowledgments and Disclosures
We would like to thank Simulations Plus, Inc. for providing us with an academic license for ADMET Predictor™, ADMET Modeler™, and MedChem Designer™. Additionally, we would like to acknowledge Dr. Michael Lawless, Senior Principle Scientist at Simulations Plus, for his insightful suggestions throughout this project.
- 8.Staff NP, Grisold A, Grisold W, Windebank AJ. Chemotherapy-induced peripheral neuropathy: a current review. Ann Neurol. 2017.Google Scholar
- 12.Council NR. Toxicity testing in the 21st century: a vision and a strategy: National Academies Press; 2007.Google Scholar
- 22.Makhaeva GF, Radchenko EV, Baskin II, Palyulin VA, Richardson RJ, Zefirov NS. Combined QSAR studies of inhibitor properties of O-phosphorylated oximes toward serine esterases involved in neurotoxicity, drug metabolism and Alzheimer's disease. SAR QSAR Environ Res. 2012;23(7–8):627–47.PubMedCrossRefGoogle Scholar
- 39.Yuan Y, Zaidi SA, Elbegdorj O, Aschenbach LC, Li G, Stevens DL, et al. Design, synthesis, and biological evaluation of 14-heteroaromatic-substituted naltrexone derivatives: pharmacological profile switch from mu opioid receptor selectivity to mu/kappa opioid receptor dual selectivity. J Med Chem. 2013;56(22):9156–69.PubMedPubMedCentralCrossRefGoogle Scholar